-
11.
公开(公告)号:US20240117059A1
公开(公告)日:2024-04-11
申请号:US18533360
申请日:2023-12-08
发明人: Tomoyuki Igawa , Atsuhiko Maeda , Futa Mimoto , Taichi Kuramochi
IPC分类号: C07K16/28
CPC分类号: C07K16/2866 , C07K16/2812 , A61K2039/505 , C07K2317/34 , C07K2317/524 , C07K2317/526 , C07K2317/94
摘要: The present invention provides: a modified FcRn-binding domain having an enhanced affinity for the Fc Receptor neonatal (FcRn) at neutral pH; an antigen-binding molecule comprising said FcRn-binding domain, which has low immunogenicity, high stability and form only a few aggregates; a modified antigen-binding molecule having an increased FcRn-binding activity at neutral or acidic pH without an increased binding activity at neutral pH for a pre-existing anti-drug antibody; use of the antigen-binding molecules for improving antigen-binding molecule-mediated antigen uptake into cells; use of the antigen-binding molecules for reducing the plasma concentration of a specific antigen; use of the modified FcRn-binding domain for increasing the total number of antigens to which a single antigen-binding molecule can bind before its degradation; use of the modified FcRn-binding domain for improving pharmacokinetics of an antigen-binding molecule; methods for decreasing the binding activity for a pre-existing anti-drug antibody; and methods for producing said antigen-binding molecules.
-
公开(公告)号:US20240115578A1
公开(公告)日:2024-04-11
申请号:US18271529
申请日:2022-01-28
发明人: Jotaro SATO , Chie EMOTO , Mikiko NAKAMURA
IPC分类号: A61K31/5377 , A61P35/00
CPC分类号: A61K31/5377 , A61P35/00
摘要: ALK abnormalities are widely found in a variety of pediatric malignant solid tumors, and ALK inhibitors against ALK abnormalities are considered an important target in the development of treatment in the field of pediatric oncology.
According to the present invention, it is possible to provide a pharmaceutical composition for the treatment of childhood cancer with an ALK abnormality, with a novel dosage and administration, comprising alectinib or a salt thereof, and to be used in the treatment of cancer in children under the age of 2.-
13.
公开(公告)号:US11952422B2
公开(公告)日:2024-04-09
申请号:US16769299
申请日:2018-12-04
发明人: Shun Shimizu , Shu Wen Samantha Ho , Naoka Hironiwa , Mika Sakurai , Taro Miyazaki , Tomoyuki Igawa
CPC分类号: C07K16/2809 , C07K16/2863 , C07K16/2878 , C07K16/303 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/526 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/71 , C07K2317/75 , C07K2317/92 , C40B30/04
摘要: Antigen-binding domains that are capable of binding to CD3 and CD137 but do not bind to CD3 and CD137 at the same time and methods of using the same are provided. Methods to obtain antigen binding domains which bind to two or more different antigen more efficiently are also provided.
-
公开(公告)号:US20240083939A1
公开(公告)日:2024-03-14
申请号:US18505180
申请日:2023-11-09
发明人: Tomoyuki Igawa , Zenjiro Sampei , Tetsuya Wakabayashi , Eriko Ito
CPC分类号: C07K1/22 , C07K14/70535 , C07K16/2809 , C07K16/2866 , C07K16/303 , C07K16/36 , C07K16/468 , C07K2317/52 , C07K2317/526 , C07K2317/567 , C07K2317/622 , C07K2317/66 , C07K2317/94 , C07K2319/30
摘要: The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies.
-
15.
公开(公告)号:US20240069033A1
公开(公告)日:2024-02-29
申请号:US18268470
申请日:2021-12-24
发明人: Tetsuo KOJIMA , Kaori NISHIMURA , Yugo KURIKI
IPC分类号: G01N33/68
CPC分类号: G01N33/6845
摘要: A method for screening for a molecule capable of forming a complex with a plurality of target molecules has been found by applying an affinity-based method for recovering a candidate molecule to techniques represented by Split GFP techniques. The method includes allowing a first target molecule linked to a first moiety of a protein, a second target molecule linked to a second moiety of the protein, and a library containing a plurality of test molecules to coexist, and recovering a test molecule capable of forming a complex with the first target molecule linked to the first moiety and the second target molecule linked to the second moiety by an affinity technique.
-
公开(公告)号:US20240052021A1
公开(公告)日:2024-02-15
申请号:US18157320
申请日:2023-01-20
发明人: Yoshinao RUIKE , Zenjiro SAMPEI
IPC分类号: C07K16/18 , G01N33/68 , G01N33/564 , A61K31/519
CPC分类号: C07K16/18 , G01N33/6863 , G01N33/564 , A61K31/519 , C07K2317/21 , C07K2317/24 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N2333/4716
摘要: An objective of the invention is to provide anti-C5 antibodies and methods of using the same. The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the β chain of C5 with a higher affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding an anti-C5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The invention further provides a method of producing an anti-C5 antibody comprising immunizing an animal against a polypeptide which comprises the MG1-MG2 domain of the β chain of C5. Anti-C5 antibodies of the present invention may be for use as a medicament. Anti-C5 antibodies of the present invention may be for use in treating a complement-mediated disease or condition which involves excessive or uncontrolled activation of C5. Anti-C5 antibodies of the present invention may be for use in enhancing the clearance of C5 from plasma.
-
公开(公告)号:US11896579B2
公开(公告)日:2024-02-13
申请号:US17358933
申请日:2021-06-25
IPC分类号: A61K31/404 , A61K45/06 , A61K31/4545 , A61K31/506 , A61K31/5355 , A61K39/395 , A61K31/44
CPC分类号: A61K31/404 , A61K31/44 , A61K31/4545 , A61K31/506 , A61K31/5355 , A61K39/395 , A61K45/06
摘要: The present invention relates to a drug that is for treating or preventing cancer, that is effective in the treatment of cancer, and that comprises a combination of an ALK inhibitor and a VEGF inhibitor. The present invention also relates to a method for treating or preventing cancer and a method for inhibiting tumor growth.
-
18.
公开(公告)号:US20240043526A1
公开(公告)日:2024-02-08
申请号:US18340168
申请日:2023-06-23
发明人: Takako MATSUOKA , Manabu ARAKI , Takashi YAMAMURA
IPC分类号: C07K16/24 , A61K39/395
CPC分类号: C07K16/248 , A61K39/395 , A61K45/06
摘要: It has become clear that the therapeutic effect of an IL-6 inhibitor for IL-6- and neutrophil-associated diseases can be predicted using the expression level of neutrophil-associated genes as an indicator. It has also become clear that an IL-6 inhibitor is effective for the treatment of IL-6- and neutrophil-associated diseases in patients with high expression levels of neutrophil-associated genes. The present invention provides a method for selecting cases of IL-6- and neutrophil-associated diseases in which treatment with an IL-6 inhibitor is effective, as well as a method for effectively treating patients with IL-6- and neutrophil-associated diseases and with high expression levels of neutrophil-associated genes.
-
公开(公告)号:US20240043515A1
公开(公告)日:2024-02-08
申请号:US18022342
申请日:2021-08-27
发明人: Hitoshi KATADA , Kanako TATSUMI
CPC分类号: C07K16/22 , A61P35/00 , C07K2317/52 , C07K2317/14
摘要: In one non-limiting embodiment, polypeptides comprising a variant Fc region which contains amino acid alterations in a parent Fc region, and methods for producing such polypeptides, are provided.
-
公开(公告)号:US11891457B2
公开(公告)日:2024-02-06
申请号:US17011815
申请日:2020-09-03
发明人: Shiori Kariyuki , Takeo Iida , Miki Kojima , Ryuichi Takeyama , Mikimasa Tanada , Tetsuo Kojima , Hitoshi Iikura , Atsushi Matsuo , Takuya Shiraishi , Takashi Emura , Kazuhiko Nakano , Koji Takano , Kousuke Asou , Takuya Torizawa , Ryusuke Takano , Nozomi Hisada , Naoaki Murao , Atsushi Ohta , Kaori Kimura , Yusuke Yamagishi , Tatsuya Kato
IPC分类号: C07K7/64 , C07K1/113 , C12P21/02 , C07K7/08 , C07K19/00 , C07H21/04 , C07K5/087 , C07K5/103 , C07K7/06 , C07K11/00 , C07K11/02 , A61K38/00
CPC分类号: C07K7/64 , C07H21/04 , C07K1/113 , C07K5/0812 , C07K5/1013 , C07K7/06 , C07K7/08 , C07K11/00 , C07K11/02 , C07K19/00 , C12P21/02 , A61K38/00
摘要: An object of the present invention is to provide methods of discovering drugs effective for tough targets, which have conventionally been discovered only with difficulty. The present invention relates to novel methods for cyclizing peptide compounds, and novel peptide compounds and libraries comprising the same, to achieve the above object.
-
-
-
-
-
-
-
-
-